DocMorris AG reaffirmed earnings guidance for the year 2023. The company continues to focus in particular on its action plan to further strengthen the sustainable basis for profitability and future revenue growth. Regardless of the ramp-up speed of electronic prescriptions, management confirms its 2023 targets communicated in March 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.85 CHF | +0.21% | -2.87% | -1.22% |
Apr. 23 | DOCMORRIS : Deutsche Bank remains its Buy rating | ZD |
Apr. 19 | DOCMORRIS : Hauck & Aufhauser gives a Buy rating | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.22% | 1B | |
-31.33% | 15.83B | |
-22.89% | 12.31B | |
-24.53% | 6.59B | |
+12.51% | 6.45B | |
-12.43% | 5.94B | |
-0.15% | 4.66B | |
+62.00% | 4.59B | |
-5.94% | 3.96B | |
-8.76% | 3.55B |
- Stock Market
- Equities
- ROSE Stock
- News DocMorris AG
- DocMorris AG Reaffirms Earnings Guidance for the Year 2023